Monday 12 October 2026
Export all AMGN data to Excel Powerpack
Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
414.87
7.43
+1.82%
Follow AMGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 91.47% | 101.32% | 106.10% | 81.71% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
8 | 8 | 7 | 7 | |
| 9.53% | 8.58% | 8.45% | 7.74% | ||
ROIC |
12.98% | 12.12% | 10.48% | 9.90% | |
Return on Tangible Assets |
48.56% | 52.93% | 67.16% | 52.61% | |
Average Days of Receivables |
97.99 | 89.61 | 95.05 | 86.15 | |
Free Cash Flow per Share |
18.84 | 15.92 | 15.06 | 21.45 | |
Free Cash Flow |
10,175.00 | 8,597.00 | 8,100.00 | 11,539.00 | |
Capital Expenditures |
(2,303.00) | (2,159.00) | (1,858.00) | (1,587.00) | |
| Other line items | |||||
Cash ROIC |
12.26% | 10.94% | 11.19% | 15.67% | |
Accounts Receivable Turnover |
4.03 | 4.31 | 4.50 | 4.55 | |
Accounts Payable Turnover |
3.95 | 4.42 | 5.63 | 4.88 | |
Inventory Turnover |
1.81 | 1.83 | 1.82 | 1.78 | |
Average Days of Payables |
90.05 | 90.69 | 71.77 | 85.10 | |
Days of Inventory on Hand |
195.50 | 191.14 | 188.76 | 190.28 | |
Tax Rate |
(0.15) | (0.14) | (0.14) | (0.15) | |
Research and Development Expense of Revenue |
20.03% | 20.16% | 19.79% | 19.05% | |
Selling, General and Administrative Expense of Revenue |
18.42% | 18.71% | 19.18% | 19.39% | |
Share Based Compensation of Revenue |
1.29% | 1.30% | 1.34% | 1.40% | |
Interest Coverage |
4.28 | 3.93 | 3.30 | 3.04 | |
Operating CF/Net income |
1.43 | 1.38 | 1.29 | 1.87 | |
Depreciation/Fixed assets |
0.59 | 0.64 | 0.80 | 0.92 | |
Capex/Depreciation |
(0.45) | (0.41) | (0.29) | (0.24) | |
Revenue per Share |
70.55 | 68.93 | 68.31 | 66.86 | |
Operating CF per Share |
23.11 | 19.92 | 18.51 | 24.40 | |
Capex per Share |
(4.26) | (4.00) | (3.45) | (2.95) | |
Capex to Sales |
0.06 | 0.06 | 0.05 | 0.04 |
Columns are period end dates